

Eli Lilly Prevails in Federal Circuit on Alimta Patent

August 2019

On August 9th, the United States Court of Appeals for the Federal Circuit ruled in favor of Williams & Connolly client Eli Lilly, affirming two trial court judgments holding generic competitors Dr. Reddy's' and Hospira's proposed products would infringe Lilly's patent protecting its blockbuster anti-cancer drug Alimta®. This victory follows Lilly's two previous wins before the Federal Circuit, where the court in a unanimous opinion affirmed two district court judgments concerning the Alimta® patent, and upheld three PTAB decisions denying *inter partes* review of the same patent. Williams & Connolly represented Lilly in both of those cases as well.

Through these repeated victories, Williams & Connolly has helped secure Eli Lilly's continued patent protection for Alimta®, a product with more than \$1 billion in annual U.S. revenue.

Eli Lilly is represented by **Adam Perlman**, **Dov Grossman**, **David Krinsky**, **Galina Fomenkova**, **Luke McCloud**, and **Andrew Lemens**.

Press Contacts

Adam Perlman

aperlman@wc.com

D 202-434-5244

Dov Grossman

dgrossman@wc.com

D 202-434-5812

David Krinsky

dkrinsky@wc.com

D 202-434-5338

Luke McCloud

lmccloud@wc.com

D 202-434-5586

Andrew Lemens

alemens@wc.com

D 202-434-5132